<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00243594</url>
  </required_header>
  <id_info>
    <org_study_id>2004-3126</org_study_id>
    <secondary_id>2004-3126</secondary_id>
    <secondary_id>KUN99-1950</secondary_id>
    <nct_id>NCT00243594</nct_id>
  </id_info>
  <brief_title>Dendritic Cell Vaccination in Melanoma Patients Scheduled for Regional Lymph Node Dissection</brief_title>
  <official_title>Active Immunization of Patients With Stage III and IV Melanoma in Whom a Regional Lymph Node Dissection is Planned, With Peptide-Pulsed Dendritic Cells: Evaluation of in Vivo Immune and Clinical Response and Migration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dutch Cancer Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dendritic cells (DCs) are the professional antigen-presenting cells of the immune system. As
      such they are currently used in clinical vaccination protocols in cancer patients, and both
      immunological and clinical responses have been observed. For these therapies accurate
      delivery to target organs is essential. Correct delivery and subsequent migration of
      vaccinated DCs to regional lymph nodes is of paramount importance for effective stimulation
      of the immune system. Currently it is not known what the best route of administration is for
      DC vaccines.

      Using magnetically labeled DCs, we investigate the potential of MRI cell tracking to monitor
      DC therapy. This is investigated in stage III/IV melanoma patients in whom a regional lymph
      node dissection is scheduled. Autologous monocyte-derived DCs are labeled with the clinically
      approved superparamagnetic iron oxide (SPIO) formulation Endorem and 111In-oxine and injected
      either in the skin or directly in lymph nodes under ultrasound guidance. Two days after
      vaccination patients are monitored with scintigraphy and MR imaging. Lymph nodes are then
      resected. Subsequently patients receive 3 more vaccination with DCs. During and after therapy
      immune responses against the used melanoma peptides are monitored.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 1999</start_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immune response</measure>
    <time_frame>during the first 10 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Migration efficacy</measure>
    <time_frame>during the first 1-2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical response</measure>
    <time_frame>during the first 10 years</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Melanoma Stage III or IV</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Peptide-pulsed dendritic cells</intervention_name>
    <description>peptide-pulsed dendritic cells</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        Histologically documented evidence of melanoma

        Stage III-IV melanoma according to the 2001 AJCC criteria

        Radical lymph node dissection planned, either with curative (stage III) or palliative
        (stage IV) intent

        Melanoma expressing gp100 (compulsory) and tyrosinase (non-compulsory)

        HLA-A2.1 phenotype according to lymphocyte HLA typing

        ECOG performance status 0-1, life expectancy &gt; 3 months

        Age 18-75 years

        Interval since last prior chemotherapy, immunotherapy or radiotherapy at least 4 weeks, no
        residual toxicity of prior treatment.

        WBC &gt; 3.0 x 109/l, lymphocytes &gt; 0.8 x 109/l, platelets &gt; 100 x 109/l, serum creatinine &lt;
        150 μmol/l, serum bilirubin &lt; 25 μmol/l

        Written informed consent

        Expected adequacy of follow-up

        Exclusion criteria:

        No clinical signs of CNS metastases, in patients with a clinical suspicion of other
        metastases diagnostic tests should be performed to exclude this.

        No concomitant use of corticosteroids or other immunosuppressive agents

        No history of second malignancy within the last 5 years. Adequately treated basal carcinoma
        of skin or carcinoma in situ of cervix is acceptable within this period

        No serious concomitant disease, no active infections. No autoimmune disease or organ
        allografts, no clinical suspicion of HIV or Hepatitis B

        No contra-indications for MRI-scanning: claustrophobia, pacemaker or pacemaker threads,
        cerebral clips or artificial heartvalves, internal hearing prosthesis No known allergy to
        shell fish (contains KLH)

        No pregnant or lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof. C.J.A. Punt, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Prof. C.G. Figdor, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radboud University Nijmegen Medical Centre</name>
      <address>
        <city>Nijmegen</city>
        <state>PO Box 9101</state>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.umcn.nl</url>
    <description>Home page of the Radboud University Nijmegen Medical Centre</description>
  </link>
  <link>
    <url>http://www.ncmls.nl/</url>
    <description>Website of the department of Tumor Immunology of the Nijmegen Centre for Molecular Life Sciences of the Radboud University Nijmegen Medical Centre</description>
  </link>
  <reference>
    <citation>de Vries IJ, Bernsen MR, Lesterhuis WJ, Scharenborg NM, Strijk SP, Gerritsen MJ, Ruiter DJ, Figdor CG, Punt CJ, Adema GJ. Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. J Clin Oncol. 2005 Aug 20;23(24):5779-87.</citation>
    <PMID>16110035</PMID>
  </reference>
  <reference>
    <citation>Lesterhuis WJ, de Vries IJ, Adema GJ, Punt CJ. Dendritic cell-based vaccines in cancer immunotherapy: an update on clinical and immunological results. Ann Oncol. 2004;15 Suppl 4:iv145-51. Review.</citation>
    <PMID>15477299</PMID>
  </reference>
  <reference>
    <citation>Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mapping the way. Nat Med. 2004 May;10(5):475-80. Review.</citation>
    <PMID>15122249</PMID>
  </reference>
  <reference>
    <citation>de Vries IJ, Lesterhuis WJ, Scharenborg NM, Engelen LP, Ruiter DJ, Gerritsen MJ, Croockewit S, Britten CM, Torensma R, Adema GJ, Figdor CG, Punt CJ. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res. 2003 Nov 1;9(14):5091-100.</citation>
    <PMID>14613986</PMID>
  </reference>
  <reference>
    <citation>De Vries IJ, Krooshoop DJ, Scharenborg NM, Lesterhuis WJ, Diepstra JH, Van Muijen GN, Strijk SP, Ruers TJ, Boerman OC, Oyen WJ, Adema GJ, Punt CJ, Figdor CG. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res. 2003 Jan 1;63(1):12-7.</citation>
    <PMID>12517769</PMID>
  </reference>
  <reference>
    <citation>de Vries IJ, Eggert AA, Scharenborg NM, Vissers JL, Lesterhuis WJ, Boerman OC, Punt CJ, Adema GJ, Figdor CG. Phenotypical and functional characterization of clinical grade dendritic cells. J Immunother. 2002 Sep-Oct;25(5):429-38.</citation>
    <PMID>12218781</PMID>
  </reference>
  <reference>
    <citation>Adema GJ, de Vries IJ, Punt CJ, Figdor CG. Migration of dendritic cell based cancer vaccines: in vivo veritas? Curr Opin Immunol. 2005 Apr;17(2):170-4. Review.</citation>
    <PMID>15766677</PMID>
  </reference>
  <reference>
    <citation>de Vries IJ, Lesterhuis WJ, Barentsz JO, Verdijk P, van Krieken JH, Boerman OC, Oyen WJ, Bonenkamp JJ, Boezeman JB, Adema GJ, Bulte JW, Scheenen TW, Punt CJ, Heerschap A, Figdor CG. Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol. 2005 Nov;23(11):1407-13. Epub 2005 Oct 30.</citation>
    <PMID>16258544</PMID>
  </reference>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2005</study_first_submitted>
  <study_first_submitted_qc>October 21, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2005</study_first_posted>
  <last_update_submitted>February 18, 2009</last_update_submitted>
  <last_update_submitted_qc>February 18, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 19, 2009</last_update_posted>
  <responsible_party>
    <name_title>C.J.A. Punt, MD, PhD</name_title>
    <organization>Radboud University Nijmegen Medical Centre</organization>
  </responsible_party>
  <keyword>Dendritic cells</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Vaccination</keyword>
  <keyword>Melanoma</keyword>
  <keyword>Peptides</keyword>
  <keyword>MRI</keyword>
  <keyword>Scintigraphy</keyword>
  <keyword>Immune response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

